Sirna Therapeutics
From Wikipedia, the free encyclopedia
Sirna Therapeutics (NASDAQ: RNAI) is a San Francisco, California based biotechnology company that explores the use of RNA interference in human disease therapy. Sirna's development pipeline includes several small interfering RNA (siRNA) drugs, thought to stably silence the expression of specific disease-related genes. Sirna's clinical trial of an siRNA-based treatment for age-related macular degeneration is the first such trial for an siRNA drug.[1][2]
Sirna Therapeutics was acquired by Merck & Co. in 2006 in a deal worth $1.1 billion.[3]
[edit] References
- ^ Ocular Therapeutic Pipeline. Retrieved on 2007-02-12.
- ^ Sah D (2006). "Therapeutic potential of RNA interference for neurological disorders". Life Sci 79 (19): 1773-80. PMID 16815477
- ^ Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc.
[edit] External links
This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
